Royal Bank of Canada’s Celyad Oncology SA American Depositary Shares CYAD Stock Holding History

Royal Bank of Canada’s Portfolio CYAD Stock Details CYAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-70	Closed	-$2K	–	6845
2016 Q3	$2K	Buy	+70	New	+$1.69K	﹤0.01%	6215

Other funds holding CYAD

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Zurich Cantonal Bank Zurich, Switzerland $52.2B AUM 40.82% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada's CYAD Position: Q4 2016 in Review

Royal Bank of Canada sold out of Celyad Oncology SA American Depositary Shares (CYAD) in Q4 2016, closing a stake of 70 shares — an estimated $2K sold.

Royal Bank of Canada first reported a position in CYAD in Q3 2016 and held it in 1 quarter. The position peaked at $2K in Q3 2016. 6 funds tracked by Wall St. Rank hold CYAD as of Q4 2016.

Royal Bank of Canada reported no remaining Celyad Oncology SA American Depositary Shares position as of Q4 2016 after selling out during the quarter.
Royal Bank of Canada sold 70 Celyad Oncology SA American Depositary Shares shares in Q4 2016, an estimated $2K.
Royal Bank of Canada first reported a position in Celyad Oncology SA American Depositary Shares in Q3 2016 and held it in 1 quarter.
Royal Bank of Canada's Celyad Oncology SA American Depositary Shares position peaked at $2K in Q3 2016.
6 funds tracked by Wall St. Rank held Celyad Oncology SA American Depositary Shares as of Q4 2016.

Based on Royal Bank of Canada's 13F filing for Q4 2016, filed 14 Feb 2017.